{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19","upperLimit":"35","value":"26"},{"groupId":"OG001","lowerLimit":"22","upperLimit":"49","value":"35"},{"groupId":"OG002","lowerLimit":"39","upperLimit":"58","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"107"}],"units":"Participants"}],"description":"CLL (subset of patients in the Relapsed Indolent Non-Hodgkin Lymphoma group): 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, \\>100000/μL platelets, \\>11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions.\n\nWaldenstrom (subset of patients in the Uncommon Lymphomas group): \\>50% reduction in serum immunoglobulin M(IgM) levels (by serum protein electrophoresis (SPEP)) during any point while in this study, and no appearance of new lesions.\n\nAll others: at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Study 1.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG000","title":"Relapsed Aggressive Non-Hodgkin Lymphoma"},{"description":"Study 2.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG001","title":"Relapsed Indolent Non-Hodgkin Lymphoma"},{"description":"Study 3. Includes Hodgkin's lymphomas.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG002","title":"Uncommon Lymphomas"}],"paramType":"NUMBER","populationDescription":"276 out of 277 were analyzed for response. One patient was excluded because of patient refusal before starting treatment.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Tumor Response, Defined by Disease: Chronic Lymphocytic Leukemia(CLL): Clinical Complete or Complete or Nodular Partial or Partial Remission, Waldenstrom: Complete or Partial Response, All Others: Complete or Complete Unconfirmed or Partial Response.","type":"PRIMARY","unitOfMeasure":"percentage of patients in group"}